MedWatch

Novo rival faces massive challenges

US pharma giant, Eli Lilly, is racing the clock. Within the next year, three of the company’s drugs, accounting for 40 % of turnover, are set to go off patent. Looking ahead to 2017, the patent expirations are even greater, covering 63 % of turnover. Too broad a focus and stricter regulatory requirements are to blame.

Foto: Eli Lilly

Zyprexa has already fallen victim to the cold grasp of the generics industry. Within the next year, the same will happen to Cymbalta, Evista and Humalog, while another three drugs go off patent by 2017.

That is the harsh reality for US pharmaceutical giant, Eli Lilly.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier